Yahoo Finance BELLUS Health Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
BELLUS Health (TSE:BLU) Third Quarter 2022 Results
Key Financial Results
Net loss: US$24.7m (loss widened by 8.0% from 3Q 2021).
US$0.20 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
BELLUS Health Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 28%. Earnings per share (EPS) missed analyst estimates by 15%.
Looking ahead, revenue is forecast to grow 92% p.a. on average during the next 3 years, compared to a 69% growth forecast for the Biotechs industry in Canada.
Performance of the Canadian Biotechs industry.
The company's shares are up 6.4% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for BELLUS Health (2 make us uncomfortable) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
